Generalised tonic-clonic seizures and convulsive status epilepticus

Select language:
Permalink
On this page

    Last updated: October 2024

     

    Generalised tonic-clonic seizures are involuntary movements of both sides of the body associated with impaired or loss of consciousness. They result from abnormal brain activity.

     

    Most seizures are brief (less than 5 minutes) and resolve spontaneously. They may occur once or may recur.

     

    In young children, seizures frequently occur in the context of fever, with no underlying causes. These are defined as "febrile seizures".

     

    A seizure lasting longer than 5 minutes or 2 or more seizures in 5 minutes without complete restoration of baseline consciousness between seizures is defined as "status epilepticus" [1] Citation 1. Lowenstein DH, Bleck T, Macdonald RL. It’s Time to Revise the Definition of Status Epilepticus. Epilepsia. 1999;40(1):120-122. 
    https://doi.org/10.1111/j.1528-1157.1999.tb02000.x
    [2] Citation 2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocrit Care. 2012;17:3-23.
    https://higherlogicdownload.s3.amazonaws.com/NEUROCRITICALCARE/b8b3b384-bfb9-42af-bb55-45973d5054a4/UploadedImages/Documents/Guidelines/SE_Guidelines_NCS_0412.pdf
    . Status epilepticus is a medical emergency requiring immediate management. The longer a seizure lasts, the more difficult it is to stop, and the greater the risk for permanent brain damage and death.

     

    In pregnancy and the postpartum period, seizures may be a manifestation of eclampsia. Refer to Essential obstetric and newborn care, MSF. 

    Clinical features

    During a seizure

    • contraction of muscles, including respiratory muscles (tonic phase), followed by rhythmic jerking of the arms and legs (clonic phase)

    and

    • loss of consciousness

    These signs may be associated with loss of urine, breathing difficulty, and cyanosis.

     

    Immediately after a seizure (postictal phase)

    The patient experiences fatigue and temporary symptoms such as confusional state, headache, memory loss, focal deficits. Recovery usually occurs within 30 to 60 minutes [3] Citation 3. Pottkämper JCM, Hofmeijer J, Van Waarde JA, Van Putten MJAM. The postictal state — What do we know? Epilepsia. 2020;61(6):1045-1061.
    https://doi.org/10.1111/epi.16519
    but may be delayed.

    First aid during a seizure

    • Note the time. Call for help.
    • Protect from falls and trauma, loosen clothing.
    • Maintain airway, place patient in recovery position to avoid aspiration, do not put anything in the mouth.
    • Treat hypoglycaemia if present or administer glucose if unable to measure capillary blood glucose immediately (see Hypoglycaemia, Chapter 1).
    • Depending on the context:

      • Administer oxygen if available.

      • If febrile seizures are likely, see Febrile seizures.

      • In adults, thiamine (100 mg by IV infusion in 100 ml 0.9% NaCl over 30 minutes) may be administered at the same time as glucose if vitamin B1 deficiency is suspected (e.g. in case of alcohol-related seizures) a Citation a. Thiamine should be administered at the same time as glucose because glucose may precipitate Wernicke's encephalopathy in patients with chronic alcohol consumption. Treatment should be continued for 3 to 5 days with thiamine PO (100 to 200 mg once daily) or IM (100 mg once daily). .

    • If seizures stop spontaneously in 5 minutes or less, see Postictal management.

    Febrile seizures

    Febrile seizures frequently occur in children aged 6 months to 5 years with fever (usually due to viral infection) and no signs of central nervous system (CNS) infection, metabolic disturbances, or history of afebrile seizures [4] Citation 4. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child With Simple Febrile Seizures. Pediatrics. 2008;121(6):1281-1286.
    https://doi.org/10.1542/peds.2008-0939
    . They may be either "simple" or "complex".

     

     

    • A simple febrile seizure is defined as a single generalised seizure, without focal signs, that lasts less than 15 minutes, and does not recur within a 24-hour period [4] Citation 4. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child With Simple Febrile Seizures. Pediatrics. 2008;121(6):1281-1286.
      https://doi.org/10.1542/peds.2008-0939
      . Most of these seizures last less than 5 minutes and if so, no antiseizure treatment is required. The risk of subsequent epilepsy is low after this type of seizure. Observe the child at least until full recovery, and discharge when child returns to neurological baseline. Give instructions for home-based management: symptomatic treatment of fever to make the child more comfortable (see Fever, Chapter 1) and of underlying viral infection if relevant.

     

    • A complex febrile seizure is a seizure meeting at least one the following criteria: presence of focal signs, a duration more than 15 minutes, or multiple seizures within a 24-hour period [4] Citation 4. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child With Simple Febrile Seizures. Pediatrics. 2008;121(6):1281-1286.
      https://doi.org/10.1542/peds.2008-0939

     

    Status epilepticus

    In case of status epilepticus, start antiseizure medication (ASM).

     

     
    • ASMs may cause respiratory depression, bradycardia, and hypotension, especially in children and older patients. 
    • During and after ASM administration:
      • have ventilation equipment (Ambu and mask) and solutions for fluid replacement ready for use,
      • monitor RR, SpO2, HR, and BP at least every 15 minutes until stable.
    • Never administer ASMs by rapid IV injection. Reduce the administration rate in the event of drop in RR, HR, or BP.

    Step 1 - First-line ASM treatment

    • Administer one of the following benzodiazepines (BZD). The choice depends on the situation, i.e. if seizures occur in pre-hospital or hospital setting.
    • In any case, do not administer more than 2 doses of BZD.

    Status epilepticus in pre-hospital setting

    • Administer midazolam (5 mg/ml solution) by buccal or intranasal route or diazepam (5 mg/ml solution) by rectal route. For doses to be administered, see Table 1.
    • If seizures do not stop 5 minutes after the first dose of BZD, readminister the same dose. 
    • If seizures do not stop after the second dose of BZD, refer urgently to hospital for treatment with second-line ASM(s).
    • If seizures stop after 1 or 2 doses of BZD, refer to hospital for further management (aetiologic treatment and potential maintenance treatment).
    • While awaiting transfer, monitor vital signs, administer oxygen if available to maintain SpO2 > 94%. If seizures stop, see Postictal management.

    Status epilepticus in hospital setting

    Check whether a BZD has been administered before arrival at the hospital and the number of doses. If one dose was administered, give a second dose. If 2 doses were administered, start Step 2 - Second-line ASM treatment.

     

    If no pre-hospital dose of BZD was administered:

    • If IV or IO access: diazepam (5 mg/ml solution) by slow IV injection (over 3 to 5 minutes). For doses to be administered, see Table 1.
    • If no IV or IO access: midazolam (5 mg/ml solution) by buccal or intranasal route or midazolam (1 mg/ml solution) by IM route or diazepam (5 mg/ml solution) by rectal route. For doses to be administered, see Table 1.
    • If seizures do not stop 5 minutes after the first dose of BZD, readminister the same dose. 
    • If seizures do not stop after the second dose of BZD, start Step 2 - Second-line ASM treatment.
    • If seizures recur: 
      • 6 hours or more after seizures stop, restart treatment from Step 1 - First-line ASM treatment as for a new seizure,
      • Less than 6 hours after seizures stop, continue treatment at the last point, e.g.:
        • if seizures recur < 6 hours after a first dose of BZD, readminister the same dose,
        • if seizures recur < 6 hours after 2 doses of BZD, start Step 2 - Second-line ASM treatment.
    • If seizures stop after 1 or 2 doses of BZD and do not recur, see Postictal management and evaluate the need for maintenance ASM treatment.

     

    Table 1 - Dosage of benzodiazepines

     

    Age

    1 to < 4 months

    4 to < 12 months

    1 to < 3

    years

    3 to < 5 years

    5 to < 9 

    years 

    9  to < 12

    years

    ≥ 12 years  adults

    Weight

    3 to < 6

    kg

    6 to < 10

    kg

    10 to < 15 kg

    15 to < 20 kg

    20 to < 30 

    kg

    30 to < 40 

    kg

    ≥ 40 kg

    midazolam buccal (a) Citation a. Midazolam buccal route: lay the patient on their side. Withdraw the required dose using a 1 ml or 2 ml syringe. Remove the needle. Insert the tip of the syringe into the space between the gum and cheek. Administer the dose by slowly pushing the syringe plunger.  or intranasal route (b) Citation b. Midazolam intranasal route: lay the patient on their back or side. Withdraw the required dose using a 1 ml or 2 ml syringe (add an additional 0.1 ml to the calculated dose to account for the remaining liquid in the atomising device). Remove the needle. Attach the intranasal atomisation device to the syringe. Briskly push the syringe plunger to spray the dose into the nostril. The dose can be split in both nostrils to reduce irritation.  , dose in ml (5 mg/ml solution)  

     

    0.25 ml

    0.4 ml

    0.6 ml

    1 ml

    1.2 ml

    2 ml

    2 ml

    midazolam IM route, dose in ml (1 mg/ml solution)   

     

    0.6 ml

    1.2 ml

    2 ml

    3 ml

    4 ml

    6 ml

    10 ml

    diazepam rectal route (c) Citation c. Diazepam rectal route: lay the patient on their side. For volumes up to 1 ml, use a 1 ml syringe. Withdraw the required dose. Remove the needle. Insert the syringe into the rectum for a length of 1 to 3 cm (depending on age) to administer the dose. For volumes greater than 1 ml, use a 2 ml syringe and attach to the tip of the syringe a nasogastric tube n°8 cut to a length of 2 to 3 cm to administer the dose. After administration, hold the buttocks together for at least one minute. , dose in ml (5 mg/ml solution)   

     

    0.4 ml

    0.7 ml

    1.2 ml

    1.5 ml

    2 ml

    2 ml

    2 to 4 ml (d) Citation d. In patients ≥ 65 years: for diazepam rectal, do not exceed 2 ml (= 10 mg) per dose; for diazepam IV, reduce the dose by half (1 ml = 5 mg per dose).

    diazepam slow IV route, dose in ml (5 mg/ml solution)  

     

    0.25 ml

    0.4 ml

    0.6 ml

    1 ml

    1.2 ml

    2 ml

    2 ml (d) Citation d. In patients ≥ 65 years: for diazepam rectal, do not exceed 2 ml (= 10 mg) per dose; for diazepam IV, reduce the dose by half (1 ml = 5 mg per dose).

    Step 2 - Second-line ASM treatment

    Patients with no known epilepsy

    Second-line ASMs are indicated for:

    • Children, if seizures do not stop within 5 minutes of second dose of BZD.
    • All adults, even if seizures stop after 1 or 2 doses of BZD, unless a reversible cause of seizure can be quickly treated (e.g. hypoglycaemia, electrolyte disturbances).

    The choice of the ASM depends on the patient’s characteristics: age, sex, pregnancy or breastfeeding status, and comorbidities. See Table 2

    For doses to be administered, see Table 3

     

    Table 2 - Choice of a second-line antiseizure medication

     

     

    Children 1 month to < 2 years

    Girls ≥ 10 years and women

    Girls 2 to < 10 years

    Boys ≥ 2 years and men

     

    First choice

    levetiracetam (LEV) (e) Citation e. LEV can be used in all patients but with caution in patients with renal impairment or heart disorders.

    levetiracetam (LEV) (e) Citation e. LEV can be used in all patients but with caution in patients with renal impairment or heart disorders. or

    valproic acid (VPA) (f) Citation f. VPA is contraindicated:
    • in children under 2 years and patients with hepatic disease;
    • in women and girls who are or may become pregnant. Every effort should be made to find a safer alternative to VPA in pregnant women and girls. However, prolonged status epilepticus is a life-threatening condition both for the mother and the unborn child. If VPA is the only ASM available, use the lowest possible dose. 

    Second choice

    phenobarbital (PB) (g) Citation g. PB is contraindicated in patients with severe impairment of respiratory, renal or hepatic function. It should be administered with caution in children, older patients and patients with mild to moderate impairment of respiratory, renal or hepatic function.

    phenobarbital (PB) (g) Citation g. PB is contraindicated in patients with severe impairment of respiratory, renal or hepatic function. It should be administered with caution in children, older patients and patients with mild to moderate impairment of respiratory, renal or hepatic function.

    Third choice

    phenytoin (PHT) (h) Citation h. PHT is contraindicated in patients with bradycardia, atrioventricular block. It should be administered with caution in patients with hepatic impairment, heart failure, cardiac rhythm disorders, hypotension.

    phenytoin (PHT) (h) Citation h. PHT is contraindicated in patients with bradycardia, atrioventricular block. It should be administered with caution in patients with hepatic impairment, heart failure, cardiac rhythm disorders, hypotension.

    • If seizures do not stop after second-line ASM, change to another second-line ASM.
    • If seizures do not stop or recur in < 6 hours despite 2 second-line ASMs, transfer the patient to an intensive care unit for treatment of refractory status epilepticus.
    • If seizures stop after 1 or 2 second-line ASM(s), see Postictal management and Maintenance ASM treatment.

    Patients with known epilepsy

    • History taking:
      • ASM and dose taken, effectiveness.
      • Missed doses if any, and reason (e.g. forgetting, interruption due to adverse effects, shortage of medication).
    • Management:
      • Administer the IV loading dose of the medication that the patient should usually take or see Table 2.
      • If seizures do not stop, continue treatment as for patients with no known epilepsy.
      • If seizures stop after 1 or 2 second-line ASM(s), see Postictal management and Maintenance ASM treatment.

    Step 3 - Maintenance ASM treatment 

    Some patients may require maintenance treatment after the loading dose.

     

    • In children, maintenance treatment is indicated when:
      • a second-line ASM has been used to control seizures, unless a reversible cause of seizure can be quickly treated (e.g. hypoglycaemia, electrolyte disturbances),
      • 3 or more seizures occur within a 24-hour period,
      • focal signs and/or impaired consciousness persist beyond expected postictal period,
      • there is known or presumed traumatic brain injury (within 24 hours of injury),
      • there is known or presumed epilepsy.

    Unless the child has already received a loading dose, start with a loading dose, see Table 3.

     

    • In adults, maintenance treatment is indicated for all patients, unless a reversible cause of seizure can be quickly treated (e.g. hypoglycaemia, electrolyte disturbances).

     

    • If seizures do not recur, administer maintenance treatment for 48 to 72 hours and then reassess. Use oral route (or nasogastric tube). For maintenance doses to be administered, see Table 3.
    • For seizures in the context of head trauma, maintenance treatment should last 7 days.
    • In case of epilepsy, start or resume long-term treatment. See Epilepsy, Chapter 12.

    Postictal management

    • Note time of end of seizure; keep patient in recovery position; maintain airway.
    • Administer oxygen to all patients if available and especially to patients who received ASM(s). Maintain SpO2 > 94%.
    • Monitor vital signs and SpO2 every 15 minutes until stable, then every hour.
    • Closely monitor RR if the patient received BZD, PB or PHT; HR and BP (and ECG if available) if the patient received PHT.
    • Observe for further seizures.
    • As soon as possible, try to identify the underlying cause and treat it, even in patients with known epilepsy (see Frequent causes of seizures):
      • Take a detailed history and perform a full clinical examination, looking particularly for general status and focal signs.
      • Depending on assessment, perform the following tests if available:
        • capillary blood glucose, especially if not done during the seizure. Check regularly blood glucose if necessary.
        • rapid diagnostic test for malaria in endemic areas
        • CSF examination (lumbar puncture) and culture
        • white blood cell count, serum electrolytes and creatinine, liver enzymes and coagulation tests, blood culture
    • Note if patient does not return to baseline status within 30 to 60 minutes of end of seizure.

    Frequent causes of seizures

    • Febrile seizures: in young children with fever, usually in a context of a respiratory or gastrointestinal viral infection.
    • CNS infections: e.g. any meningitis (for Bacterial meningitis, see Chapter 7); severe malaria, neurocysticercosis, trypanosomiasis (see Chapter 6); cerebral toxoplasmosis, cryptococcal meningitis (see HIV infection and AIDS, Chapter 8).
    • Metabolic abnormalities: e.g. hypoglycaemia (Chapter 1), electrolyte disorders (hyponatremia, hypocalcaemia).
    • Intoxications: e.g. psychoactive drugs and alcohol, methanol, medications, neurotoxic pesticides and venoms, carbon monoxide.
    • Withdrawal from CNS depressants: e.g. alcohol (see Agitation and Acute confusional state, Chapter 11), opioids, benzodiazepines, barbiturates.
    • Use of seizure-provoking drugs: many drugs may be involved, e.g. antidepressants, antipsychotics, some antimicrobials.
    • Vitamin B deficiencies (thiamine and pyridoxine), particularly in patients with chronic alcohol consumption.
    • Epilepsy: undiagnosed epilepsy, poor adherence to treatment, ineffective treatment or abrupt stop of ASM.
    • Head trauma, CNS tumour, stroke, sepsis, encephalopathy (e.g. hypertensive, hypoxic).

    Dosage of second-line antiseizure medications

    Table 3 - Second-line antiseizure medications (loading doses and maintenance doses)

     

    ASMs Loading dose Maintenance dose

    levetiracetam

    = LEV

    500 mg in 5 ml vial (100 mg/ml)

    • Children ≥ 1 month:
      • Use diluted solution: add 3 ml (300 mg) of LEV to 17 ml of 0.9% NaCl to obtain 20 ml of solution containing 15 mg of LEV per ml.
      • Administer 40 mg/kg (max. 3 g) over 10 minutes by IV infusion using a syringe pump or by very slow IV injection. 
      • If seizures do not stop after the end of the first dose, readminister half-dose: 20 mg/kg (max. 1.5 g) as above.
      • Do not exceed the total dose of 60 mg/kg or 4.5 g.
      • Do not exceed an infusion rate of 5 mg/kg/minute.
    12 hours after the loading dose:
    • Children 1 to 5 months: 

    7 mg/kg every 12 hours PO

    • Children 6 months to 15 years:

    10 mg/kg every 12 hours PO

    • Adults (i) Citation i. Reduce dosage in patients with renal impairment.  :
      • 60 mg/kg (max. 4.5 g) single dose over 15 minutes 
      • Use diluted solution as above (15 mg/ml) if administered by IV infusion using a syringe pump.
      • Use undiluted solution if administered by IV infusion in a bag of 100 ml of 0.9% NaCl.
      • Do not exceed an infusion rate of 5 mg/kg/minute

    12 hours after the loading dose:

    • Adults: 1 to 1.5 g every 12 hours PO

    phenobarbital

    = PB

    200 mg in 1 ml ampoule (200 mg/ml)

    • Children ≥ 1 month:
      • Use diluted solution: add 1 ml (200 mg) of PB to 9 ml of 0.9% NaCl to obtain 10 ml of solution containing 20 mg of PB per ml.
      • Administer 20 mg/kg (max. 1 g) over 20 minutes by IV infusion using a syringe pump (or only if not available, using a pediatric infusion set).
      • If seizures do not stop after the end of the first dose, readminister half-dose: 10 mg/kg as above.
      • Do not exceed an infusion rate of 1 mg/kg/minute.

    12 hours after the loading dose:

    • Children 1 to 11 months: 5 to 6 mg/kg once daily PO
    • Children 1 to 5 years: 6 to 8 mg/kg once daily PO
    • Children 6 to 12 years: 4 to 6 mg/kg once daily PO
    • Children > 12 years: 1 to 3 mg/kg once daily PO
    • Adults:
      • 15 mg/kg (max. 1 g) single dose over 15 minutes 
      • Use diluted solution as above (20 mg/ml) if administered by IV infusion using a syringe pump.
      • Use undiluted solution if administered by IV infusion in a bag of 100 ml of 0.9% NaCl. 
      • Do not exceed an infusion rate of 100 mg/minute.

    12 hours after the loading dose:

    • Adults: 60 to 180 mg once daily PO

    phenytoin

    = PHT

    250 mg in 5 ml ampoule or vial (50 mg/ml)

     

     

     

     
     
    • Use a large central or peripheral vein.
    • Use a infusion set or line with a 0.2 micron filter.
    • Before and after infusion, flush the catheter with 0.9% NaCl to limit venous irritation and potential incompatibility with other drugs.
    • DO NOT DILUTE IN GLUCOSE. 
    • Do not use a line used for glucose solution.

     

    • Children ≥ 1 month and ≤ 25 kg

      • Use diluted solution: add 1 ml (50 mg) of PHT to 9 ml of 0.9% NaCl to obtain 10 ml of solution containing 5 mg of PHT per ml. 
      • Administer 20 mg/kg (max. 2 g) single dose over 20 minutes by IV infusion using a syringe pump. Only if syringe pump is not available, use a paediatric infusion set.
      • Do not exceed an infusion rate of 1 mg/kg/minute.

    12 hours after the loading dose:

    • Children: 2.5 mg/kg every 12 hours PO
    • Children > 25 kg and adults (j) Citation j. Reduce dosage in patients with hepatic impairment.

      • Add undiluted solution to a 100 ml bag of 0.9% NaCl. 
      • Administer 20 mg/kg (max. 2 g) single dose by IV infusion at the following rate:
        • ≤ 1 g or ≤ 50 kg: 20 minutes
        • > 1 g and ≤ 1.5 g or > 50 kg and ≤ 75 kg: 30 minutes
        • > 1.5 g and ≤ 2 g or > 75 kg and ≤ 100 kg: 40 minutes
      • Do not exceed an infusion rate of 50 mg/minute.

     

     

     

     

     

     

     

     

     

     

     

     

     

    12 hours after the loading dose:

    • Adults: 3 to 4 mg/kg once daily PO

     

    • Older patients (≥ 65 years)

      and adults with cardiac disorders

    • Add undiluted solution to a 100 ml bag of 0.9% NaCl. 
    • Administer 20 mg/kg (max. 2 g) single dose by IV infusion at the following rate:
      • ≤ 1 g or ≤ 50 kg: 40 minutes
      • > 1 g and ≤ 1.5 g or > 50 kg and ≤ 75 kg: 60 minutes
      • > 1.5 g and ≤ 2 g or > 75 kg and ≤ 100 kg: 80 minutes
    • Do not exceed an infusion rate of 25 mg/minute.

    valproic acid

    = VPA (or sodium valproate) (k) Citation k. For a pregnant woman, if VPA is the only ASM available, use the lowest possible loading dose (an option could be to administer 20 mg/kg over 5 minutes, then repeat the same dose only if seizures do not stop by the end of the first dose).

    400 mg in 4 ml ampoule (100 mg/ml)

    • Children ≥ 2 years: 
      • Use diluted solution: add 4 ml (400 mg) of VPA to 6 ml of 0.9% NaCl to obtain 10 ml of solution containing 40 mg of VPA per ml.
      • Administer 20 mg/kg (max. 1.5 g) over 5 minutes by IV infusion using a syringe pump or by slow IV injection.
      • If seizures do not stop after the end of the first dose, readminister the same dose: 20 mg/kg (max. 1.5 g) as above. 
      • Do not exceed the total dose of 40 mg/kg or 3 g. 
      • Do not exceed an infusion rate of 6 mg/kg/minute

    6 to 8 hours after the loading dose:

    • Children ≥ 2 years:

    5 to 7.5 mg/kg (max. 600 mg) 2 times daily PO

    • Adults (i) Citation i. Reduce dosage in patients with renal impairment. :
      • 40 mg/kg (max. 3 g) single dose over 10 minutes 
      • Use diluted solution as above (40 mg/ml) if administered by IV infusion using a syringe pump.
      • Use undiluted solution if administered by IV infusion in a bag of 100 ml of 0.9% NaCl. 
      • Do not exceed an infusion rate of 6 mg/kg/minute.

    12 hours after the loading dose:

    • Adults: 1 g 2 times daily PO 

     

     

     

     

    Footnotes
    • (a)Thiamine should be administered at the same time as glucose because glucose may precipitate Wernicke's encephalopathy in patients with chronic alcohol consumption. Treatment should be continued for 3 to 5 days with thiamine PO (100 to 200 mg once daily) or IM (100 mg once daily).
    • (a)Midazolam buccal route: lay the patient on their side. Withdraw the required dose using a 1 ml or 2 ml syringe. Remove the needle. Insert the tip of the syringe into the space between the gum and cheek. Administer the dose by slowly pushing the syringe plunger.
    • (b)Midazolam intranasal route: lay the patient on their back or side. Withdraw the required dose using a 1 ml or 2 ml syringe (add an additional 0.1 ml to the calculated dose to account for the remaining liquid in the atomising device). Remove the needle. Attach the intranasal atomisation device to the syringe. Briskly push the syringe plunger to spray the dose into the nostril. The dose can be split in both nostrils to reduce irritation. 
    • (c)Diazepam rectal route: lay the patient on their side. For volumes up to 1 ml, use a 1 ml syringe. Withdraw the required dose. Remove the needle. Insert the syringe into the rectum for a length of 1 to 3 cm (depending on age) to administer the dose. For volumes greater than 1 ml, use a 2 ml syringe and attach to the tip of the syringe a nasogastric tube n°8 cut to a length of 2 to 3 cm to administer the dose. After administration, hold the buttocks together for at least one minute.
    • (d) In patients ≥ 65 years: for diazepam rectal, do not exceed 2 ml (= 10 mg) per dose; for diazepam IV, reduce the dose by half (1 ml = 5 mg per dose).
    • (e) LEV can be used in all patients but with caution in patients with renal impairment or heart disorders.
    • (f)VPA is contraindicated:
      • in children under 2 years and patients with hepatic disease;
      • in women and girls who are or may become pregnant. Every effort should be made to find a safer alternative to VPA in pregnant women and girls. However, prolonged status epilepticus is a life-threatening condition both for the mother and the unborn child. If VPA is the only ASM available, use the lowest possible dose. 
    • (g) PB is contraindicated in patients with severe impairment of respiratory, renal or hepatic function. It should be administered with caution in children, older patients and patients with mild to moderate impairment of respiratory, renal or hepatic function.
    • (h) PHT is contraindicated in patients with bradycardia, atrioventricular block. It should be administered with caution in patients with hepatic impairment, heart failure, cardiac rhythm disorders, hypotension.
    • (i) Reduce dosage in patients with renal impairment.
    • (j)Reduce dosage in patients with hepatic impairment.
    • (k)For a pregnant woman, if VPA is the only ASM available, use the lowest possible loading dose (an option could be to administer 20 mg/kg over 5 minutes, then repeat the same dose only if seizures do not stop by the end of the first dose).
    References